2/23
05:31 pm
asnd
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Neutral
Report
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
2/23
05:31 pm
asnd
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Neutral
Report
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
2/21
05:42 am
asnd
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth [Yahoo! Finance]
Medium
Report
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth [Yahoo! Finance]
2/13
08:32 am
asnd
The Boston Globe to Host Rare Disease Summit
Low
Report
The Boston Globe to Host Rare Disease Summit
2/12
10:06 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $325.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $325.00 price target on by analysts at Stifel Nicolaus.
2/12
10:00 am
asnd
BioNJ Elects Board Officers and Trustees
Low
Report
BioNJ Elects Board Officers and Trustees
2/12
09:46 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Wedbush from $240.00 to $273.00. They now have an "outperform" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Wedbush from $240.00 to $273.00. They now have an "outperform" rating on the stock.
2/12
09:02 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
2/12
08:04 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/12
07:36 am
asnd
Ascendis Pharma FY 2025 Results: More Than A Takeover Story [Seeking Alpha]
Low
Report
Ascendis Pharma FY 2025 Results: More Than A Takeover Story [Seeking Alpha]
2/11
08:30 pm
asnd
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/11
07:59 pm
asnd
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript [Yahoo! Finance]
Low
Report
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript [Yahoo! Finance]
2/11
07:02 pm
asnd
Ascendis Pharma A/S Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S Q4 Earnings Call Highlights [Yahoo! Finance]
2/11
04:01 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Low
Report
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
2/6
03:38 pm
asnd
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults [Globe and Mail, The (Toronto, Canada)]
Low
Report
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults [Globe and Mail, The (Toronto, Canada)]
2/4
04:01 pm
asnd
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
Low
Report
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
1/30
08:03 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.
1/30
02:18 am
asnd
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
Low
Report
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
1/29
07:41 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
06:00 pm
asnd
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/25
11:28 pm
asnd
Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]
Low
Report
Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]
1/25
10:40 pm
asnd
Ascendis: Why I'm Sceptical On Takeover Rumours, Long-Term Targets [Seeking Alpha]
Low
Report
Ascendis: Why I'm Sceptical On Takeover Rumours, Long-Term Targets [Seeking Alpha]
1/25
03:34 am
asnd
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
1/23
05:06 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/20
08:41 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $330.00 price target on by analysts at Wells Fargo & Company.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $330.00 price target on by analysts at Wells Fargo & Company.